Cegephar SRL
4.4 FTEThe score of Cegephar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +131 % Total assets -2 % Headcount (avg FTE) -2 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Cegephar's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 108,204 € | ||||
| Equity | 200,669 € | ||||
| Cash | 39,395 € | ||||
| EBITDA | 206,514 € | ||||
| Total assets | 787,032 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 10 Jul 2026
- Year ended 31 Dec 2024filed on 19 Jun 2025
- Year ended 31 Dec 2023filed on 14 Jun 2024
- Year ended 31 Dec 2022filed on 26 Jul 2023
- Year ended 31 Dec 2021filed on 02 Jun 2022
Cegephar's financial analysis
- Solvency25.5%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Cegephar
Cegephar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0450.412.570
- VAT number
- BE0450412570
- Peppol
- Registered · 0208:0450412570 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 16 Jun 1993
- Registered office
- 4624 Fléron
- Size
- Micro · 4.4 FTE
- Latest accounts
- 2025 · filed on 10 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Cegephar (SRL) has been based in Fléron since 1993, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 108,204 € and equity of 200,669 €; its revenue is not published. With 4.4 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 25.5%, below the median of its sector (41.5%).
Companies similar to Cegephar
Companies in the same business, of comparable size and area, outside its group.
- Apotheek Boits Retail sale of pharmaceutical products Heusden-Zolder · balance sheet 705,427 €
- Sego Pharma Retail sale of pharmaceutical products Dessel · balance sheet 939,072 €
- B.D. Farma Retail sale of pharmaceutical products Zwalm · balance sheet 562,484 €
- Pharmacie de Vellereille Retail sale of pharmaceutical products Merbes-le-Château · balance sheet €1.10m
- Gandafar Retail sale of pharmaceutical products Izegem · balance sheet 857,078 €
- Codema Pharma Retail sale of pharmaceutical products Brussels · balance sheet 375,959 €
- ETS. Vanderelst Retail sale of pharmaceutical products Saint-Ghislain · balance sheet 898,417 €
- DE French Retail sale of pharmaceutical products Ypres · balance sheet 981,157 €
Frequently asked questions about Cegephar
What is the revenue of Cegephar?
Cegephar files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Cegephar?
In Belgium, the VAT number is the company number prefixed with BE: BE0450412570 for Cegephar, if the company is VAT-registered. Its company number (CBE) is 0450.412.570.
Where is the registered office of Cegephar?
According to the CBE register, the registered office of Cegephar is in 4624 Fléron.
What is the equity of Cegephar?
At the close of the 2025 financial year, the equity of Cegephar amounts to 200,669 €, a solvency of 25.5% of total assets.
How many people work at Cegephar?
4.4 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Cegephar?
The register lists 2 active mandates at Cegephar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Cegephar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →